| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5552513 | Biomedicine & Pharmacotherapy | 2017 | 6 Pages |
Abstract
Leishmaniasis is a major public infectious disease caused by the genus Leishmania. No effective drug or vaccination strategy for leishmaniasis has been designed yet. Several intracellular Leishmania antigens have been recognized to serve in vaccination, ensuring long-lasting protection against Leishmania infection. Lipophosphoglican 3 (LPG3) as a member of the heat shock protein 90 family involves in the synthesis of lipophosphoglycan (LPG) and implicates in parasite virulence. Regarding the immunological properties of LPG3 particularly its N-terminal fragment, it would be considered as a favourable adjuvant in Leishmania vaccination.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Maryam Hosseini, Mostafa Haji-Fatahaliha, Abolfazl Miahipour, Mehdi Yousefi,